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Introduction
In the majority of cases, acute pancreatitis is a
mild and self-limiting disease, with an uneventful
recovery of the patient and a mortality of less than
2%. Nevertheless, 20%’30% of all patients develop
severe disease, characterized by the occurrence of
systemic complications and a 20%’30% risk of fatal
outcome. In recent years, research in the field of
acute pancreatitis has almost exclusively focused on
this subgroup of severely ill patients. Although this
has led to considerable progress in the treatment of
acute pancreatitis, systemic complications remain a
therapeutic challenge and a main prognostic deter-
minant of the disease (1’5).
The diagnosis, early assessment, and manage-
ment of severe acute pancreatitis remain difficult clin-
ical problems. This article presents the consensus
obtained at a meeting convened to consider the evi-
dence in these areas. The aim of the article is to pro-
vide outcome statements to guide clinical practice,
with an assessment of the supporting evidence for
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Summary: Severe pancreatitis occurs in 20%’30% of all patients with acute pancreatitis. Pancreatic
enzymes, cytokines and other active peptides, liberated from the inflamed pancreas, convert inflammation of
the pancreas as a single-organ disease of the retroperitoneum to a multisystem disease. Determinations of pan-
creatic serum enzymes are still »the golden standard« for diagnosis of the acute pancreatitis. Out of clinically
significant pancreatic enzymes, pancreatic-amylase and lipase are suggested for routine clinical determination
due to available methods for their measurement. The methods are simple, and the results may be obtained
rather quickly without any special equipment. Maximal diagnostic accuracy is achieved by »cut-off« values of
182 U/L for pancreatic-amylase and 656 U/L for lipase. Treatment of patients with acute pancreatitis is based
on the initial assessment of disease severity. Early staging is based on the presence and degree of systemic fai-
lure (cardiovascular, pulmonary, and renal) and on the presence and extent of pancreatic necrosis. Individual
clinical parameters and laboratory biomarkers, although sometimes helpful, are not sufficiently accurate to reli-
able assess the severity of an acute attack. Numeric grading systems with sensitivities of about 70% are com-
monly used today as indicators of organ failure and disease severity. Contrast material-enhanced computed
tomography is used in addition to help evaluate local pancreatic morphology and the presence and extent of
pancreatic necrosis. Out of all recently studied biochemical parameters for prognostic evaluation of acute pan-
creatitis patients, the measurement of C-reactive protein concentration appeared to be the parameter with the
highest clinical accuracy. The best differentiation of moderate from severe acute pancreatitis forms is achieved
by »cut-off« CRP values of 126 mg/L, 48 hours from the onset of symptoms. For this reason, CRP measure-
ment may be used as the alternative to computerized tomography. In compliance with the postulations for evi-
dence-based medicine, the procedures related to diagnosis, prognosis and management of acute pancreatitis
are classified into four categories: certain, probable, possible and inappropriate.
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each statement. A careful assessment was made of
the strength of the available evidence (certain, pro-
bable, possible and inappropriate) (6’7).
Definition of acute pancreatitis
In 1992, a new clinically oriented classification
system for acute pancreatitis was developed (8).
Severe acute pancreatitis was defined by the presen-
ce of organ failure or local complications, especially
pancreatic necrosis. Precise definitions were provided
for organ failure and pancreatic necrosis. The so-cal-
led Atlanta classification recognizes both the patho-
morphologic and the clinical characteristics of severe
acute pancreatitis. According to this definition, severe
acute pancreatitis is associated with systemic compli-
cations, such as organ failure and/or local complica-
tions, such as necrosis, abscess, or pseudocyst. Alt-
hough the Atlanta system discriminates between lo-
cal and systemic complications of the disease, there
is, apparently, a close connection between these enti-
ties, as it is a common observation that systemic
complications are almost exclusively restricted to pa-
tients with pancreatic necrosis (9’11).
Clinical and laboratory diagnosis 
of acute pancreatitis
There are disease-specific signs or symptoms
and the diagnosis of acute pancreatitis requires a syn-
thesis of clinical, laboratory, and imaging-procedure
finding (2). Determination of serum pancreatic enzy-
mes remains the »gold standard« for the diagnosis of
acute pancreatitis. Clinical symptoms and signs are
of major importance in suspecting the disease, but
they are not accurate enough to confirm the diagno-
sis. A further aspect in the diagnosis of acute pancre-
atitis is the identification of the etiological factor (12).
In the past, measurement of numerous serum
markers has been recommended for diagnosis of
acute pancreatitis. Among these, nearly all pancrea-
tic secretory enzymes such a-amylase (EC 3.2.1.1),
lipase (EC 3.1.1.3), trypsin (EC 3.4.21.4), elastase
(EC 3.4.21.36), ribonuclease (EC 3.1.27.5), phos-
pholipase A2 (EC 3.1.1.4), and carboxypeptidase B
(EC 3.4.17.2) can be found (13’19). For only a small
number of enzymatic markers, however, was suffi-
cient data available to appreciate their value for diag-
nosis of pancreatic diseases (20). Out of clinically sig-
nificant pancreatic enzymes, pancreatic a-amylase
and lipase are suggested for routine clinical determi-
nation due to available methods for their measure-
ment. The methods are simple, and the results may
be obtained rather quickly without any special equip-
ment. Maximal diagnostic accuracy is achieved by
»cut-off« values of 182 U/L for pancreatic a-amylase
and 656 U/L for lipase (21’24). To early define the
etiology of acute pancreatic serum pancreatic enzy-
mes lack of value (25).
The development of acute pancreatitis occurs in
4–8% of patients with symptomatic gallstones.
Individuals predisposed to acute pancreatitis tend to
have small gallstones (with or without larger gallsto-
nes), a wide cystic duct and a common channel
between the biliary and pancreatic ducts. The impor-
tance of this relationship is demonstrated by the abi-
lity of urgent endoscopic sphincterotomy (ES) to
improve the outcome of a predicted severe attack
and to virtually abolish recurrent attacks in patients
who are unable to undergo cholecystectomy. Biliary
crystals are an important marker of microlithiasis or a
propensity to form further gallstones following their
passage into the duodenum following an attack. A
combination of ultrasonography and a serum liver
transaminase of > 60 U/L (< 48 hours on an attack)
are necessary to provide optimum sensitivity and
specificity for gallstones as a prompt for the use of
ERCP (endoscopic retrograde cholangiopancreatog-
raphy) and ES in severe cases. Biliary sludge as a
cause of acute pancreatitis is not proven. Twenty five
to thirty percent of patients will develop complica-
tions with a mortality of around 8%. Urgent diagnosis
of gallstones and treatment by ES can result in sub-
stantial improvement in outcome (26).
Prognosis of acute pancreatitis
Even though the diagnosis of pancreatitis has
become easier by the measurement of specific pan-
creatic enzymes there are still 30%– 40% of the fatal
cases which are first diagnosed at autopsy. It is of
utmost importance to assess the diagnosis and the
severity of acute pancreatitis in the beginning to iden-
tify those patients with severe or necrotising disease
who benefit from an early initiated intensive care ther-
apy. Additionally, in view of new therapeutical con-
cepts (e.g. antibiotic therapy in severe forms) and for
the evaluation of new drugs, patients should be sta-
ged into mild and severe disease as early as possible.
In most cases it is not possible to assess the severity
clinically on hospital admission. Up to now the »gold
standard« are imaging procedures (contrast-enhan-
ced CT) which should be reserved for the severe
cases to estimate the extent of pancreatic necrosis
(27).
The ideal predictor in blood or in urine should
be objective, reliable, inexpensive, and easy to meas-
ure, widely available, sensitive and specific. There are
varieties of mediators of the »systemic inflammatory
response syndrome« which are elevated in this dis-
ease: C-reactive protein (CRP), antiproteases, enzyme
activation peptides like trypsinogen activation peptide
and carboxypeptidase B activation peptide, PMN-
elastase, complement factors, chemokines and inter-
leukins and others. Phospholipase A2 and pancreati-
tis-associated protein, which are produced and liber-
ated during the initial phase of pancreatic damage,
have been confrmed as good early markers of seve-
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rity. However, their clinical application is inappropri-
ate at present. Trypsinogen activation peptide and
carboxypeptidase B show great promise as markers
of severity, but further development is required before
their assay can be useful clinically.
Among all these mediators, C-reactive protein is
the parameter best analyzed. It has to be taken into
account that it is not specific for acute pancreatitis
and its highest efficacy is reached after > 48 hours
after the onset of disease. However, because usually
a certain time elapses (approximately 24’48 hours)
until patients are hospitalized the time delay seems
not to a major disadvantage (28’32). Assay of CRP is
only easely available blood test in clinical practice that
is a proven discriminator of severe and mild disease
at »cut-off« level of 126 mg/L at 48 hours after the
onset of symptoms. For this reason, CRP measure-
ment may be used as the alternative to computerized
tomography (6, 33). 
Management of patients 
with acute pancreatitis
Management of patients with acute pancreatitis
is based on the early assessment of severity of dis-
ease. As clinical examination in the first 24 hours after
admission is unreliable in predicting a serious attack
of acute pancreatitis, much efforts has been made to
develop combination of criteria that might better pre-
dict severity. Ranson et al. (34) in 1974 introduced a
combination of different clinical signs and laboratory
markers as a scoring system in this disease. In the
meantime, various other clinical scores have been
employed for patients with acute pancreatitis. Among
these, the Acute Physiology and Chronic Health
Evaluation (APACHE) II score and the Glasgow crite-
ria have been most carefully evaluated (35’37). Alt-
hough scoring systems are useful, to some extent, in
the identification of patients with severe acute pan-
creatitis, their sensitivity and specificity is limited to
70%. If a multifactor system is to be used, APACHE II
score calculated at 24 hours has proven to be the
best choice. Obesity, indicated by a body mass index
greater than 30, is a reasonably reliable predictor of
severe outcome, especially if it used along with
APACHE II score (6). Another major drawback of
most scoring systems is that daily evaluation is ne-
cessary, and that it takes 3 to 4 days to achieve a reli-
able prediction of severity. A considerable percentage
of patients develop complications despite scores ha-
ving been low during the initial course. Although
scoring systems are widely used in patients with acute
pancreatitis, they are of only limited use in the pre-
diction of severe attacks. This explains why a recent
audit on the management of acute pancreatitis reve-
aled that only a minority of hospitals perform severity
stratification of patients within the first hours by using
scores (38). The major rationale for scoring in acute
pancreatitis today is the comparability of patients par-
ticipating in clinical trials. 
CT staging and the CT severity index have pro-
ved to be a reliable indicator of disease severity, hav-
ing shown an excellent correlation with the risk of
death and the development of local and systemic
complications in this population (1).
Acute pancreatitis is a disease with a variety of
symptoms. In patients in whom the disease takes a
more severe course, stabilization is mandatory, often in
a high dependency unit or intensive care unit. Aggres-
sive organ support and continuation of the prophylac-
tic antibiotics are the mainstay of treatment. When
infected necrosis has been proven by CT-guided fine
needle biopsy, surgical necrotectomy and debridement
with drainage are necessary. Enteral feeding is superi-
or to parenteral feeding even in situations of severe
pancreatitis. Further investigation into the role of selec-
tive digestive tract decontamination, by controlled ran-
domized trials, is needed (39’41).
Conclusions
There is reliable evidence to support much cur-
rent practice. Clear guidance can be given in most
areas examined, and several areas were identified
where further investigation would be helpful. Diagno-
sis using plasma concentrations of pancreatic enzy-
mes is reliable. Rapid advances are taking place in
the assessment of severity. Several new therapeutic
strategies show real promise for the reduction of
morbidity and mortality rates. Surgical debridement
is required for infected pancreatic necrosis, but is less
often necessary for sterile necrosis (1, 6). 
Acute pancreatitis is a potentially fatal disease,
with reported mortality rates ranging from zero to
almost 25 per cent, depending on severity and holds
out several areas for future investigation through ran-
domized trials. In particular, answers are required to
settle controversies surrounding use of antibiotics
and enteral nutrition. The time is ripe for a re-evalua-
tion of the indications for surgery and of operative
techniques.
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Kratak sadr`aj: Te`ak oblik bolesti se javlja kod 20%’30% pacijenata sa akutnim pankreatitisom.
Osloba|anje pankreasnih enzima, citokina i drugih aktivnih peptide iz pankreasa zahva}enog inflamacijom
uzrokuje prelaz od zapaljenja jednog organa u retroperitoneumu ka multisistemskom oboljenju. Odre|ivanje
pankreasnih enzima u serumu jo{ uvek ostaje »zlatan standard« u dijagnozi akutnog pankreatitisa. Od klini~ki
va`nih pankreasnih enzima za klini~ko rutinsko odre|ivanje preporu~uju se pankreasna a-amilaza i lipaza zbog
postojanja raspolo`ivih metoda za njihovo odre|ivanje. Metode su jednostavne, rezultat mo`e da se dobije dosta
brzo i ne zahteva posebnu opremu za odre|ivanje. Maksimalna dijagnosti~ka ta~nost se posti`e pri »cut-off«
vrednostima od 182 U/L za pankreasnu a-amilazu i 656 U/L za lipazu. Tretman pacijenata sa akutnim pankreati-
tisom se zasniva na inicijalnoj proceni te`ine oboljenja. Rana gradacija se zasniva na prisustvu i stepenu sis-
temskih o{te}enja (kardiovasdkularnih, pulmonalnih i renalnih), kao i na prisustvu i veli~ini pankreasne nekroze.
Mada individualni klini~ki parametri i laboratorijski biomarkeri mogu da budu od pomo}i, to nije dovoljno ta~no
u proceni te`ine napada. Brojni »sistemi scorova« koriste se danas kao indikatori o{te}enja organa i te`ine obol-
jenja i njihova osetljivost iznosi oko 70%. Kompjuterizovana tomografija pobolj{ana kontrastom se koristi za
dodatnu evaluaciju lokalne pankreasne morfologije, kao i stepena pankreasne nekroze. Od svih do sada ispiti-
vanih biohemijskih parametara za prognosti~ku evaluaciju pacijenata sa akutnim pankreatitisom, odre|ivanje
koncentracije C-reaktivnog proteina (CRP) predstavlja parametar sa najve}om klini~kom ta~no{}u. Najbolje raz-
likovanje blagih od te{kih oblika AP se posti`e pri »cut-off« vrednosti CRP od 126 mg/L i to 48 sati od po~etka
simptoma. Iz ovih razloga odre|ivanje CRP mo`e da se koristi kao alternativa kompjuterizovanoj tomografiji. U
skladu sa postulatima na kojima se zasniva medicina zasnovana na dokazima (eng. evidence-based medicine)
postupci vezani za prognozu i tretman akutnog pankreatitisa se klasifikuju u ~etiri kategorije: izvesni, verovatni,
mogu}i i neodgovaraju}i.
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